Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Mallinckrodt
Harvard Business School
Covington
Baxter
Cantor Fitzgerald
UBS
AstraZeneca
Boehringer Ingelheim

Generated: May 24, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,579,865

« Back to Dashboard

Which drugs does patent 8,579,865 protect, and when does it expire?

Patent 8,579,865 protects OTREXUP and is included in one NDA.

This patent has twelve patent family members in seven countries.
Summary for Patent: 8,579,865
Title:Hazardous agent injection system
Abstract: Injection systems comprising a powered injector and one or more hazardous agents are disclosed.
Inventor(s): Wotton; Paul (Stamford, CT), Sadowski; Peter L. (Woodbury, MN), Hayes; John William (Chaska, MN)
Assignee: Antares Pharma, Inc. (Ewing, NJ)
Application Number:13/257,555
Patent Claim Types:
see list of patent claims
Dosage form; Use;

Drugs Protected by US Patent 8,579,865

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Antares Pharma Inc OTREXUP methotrexate SOLUTION;SUBCUTANEOUS 204824-005 Nov 7, 2014 DISCN Yes No ➤ Sign Up ➤ Sign Up Y SUBCUTANEOUS INJECTION OF METHOTREXATE ➤ Sign Up
Antares Pharma Inc OTREXUP methotrexate SOLUTION;SUBCUTANEOUS 204824-001 Oct 11, 2013 RX Yes Yes ➤ Sign Up ➤ Sign Up Y SUBCUTANEOUS INJECTION OF METHOTREXATE ➤ Sign Up
Antares Pharma Inc OTREXUP methotrexate SOLUTION;SUBCUTANEOUS 204824-006 Mar 24, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up Y SUBCUTANEOUS INJECTION OF METHOTREXATE ➤ Sign Up
Antares Pharma Inc OTREXUP methotrexate SOLUTION;SUBCUTANEOUS 204824-002 Oct 11, 2013 RX Yes Yes ➤ Sign Up ➤ Sign Up Y SUBCUTANEOUS INJECTION OF METHOTREXATE ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,579,865

PCT Information
PCT FiledMarch 19, 2010PCT Application Number:PCT/US2010/028011
PCT Publication Date:September 23, 2010PCT Publication Number: WO2010/108116

Non-Orange Book US Patents Family Members for Patent 8,579,865

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,421,333 Hazardous agent injection system ➤ Sign Up
8,480,631 Hazardous agent injection system ➤ Sign Up
9,750,881 Hazardous agent injection system ➤ Sign Up
8,945,063 Hazardous agent injection system ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Chinese Patent Office
Daiichi Sankyo
UBS
Julphar
AstraZeneca
Baxter
Colorcon
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.